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Abstract
Breast cancer is the most common cancer in women in the western world. 
The estrogen receptor (ER) is expressed in two thirds of newly diagnosed breast cancers, so hormonal treatment is performed 
only in the receptor positive patients. The most successful ER imaging radiopharmaceutical in PET techniques is 16α-[18F]-
flouro-17β-estradiol (18F-FES). 
The diffuse large B cell lymphoma (DLBCL) is one of the most common NHL, however, non-Hodgkin lymphoma constitutes only 
4% of all primary cancers in women. The typical staging of disease is done using 18-fluorodeoksyglukose (18F-FDG) PET/CT.
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Case report
A 73-year-old female with no significant medical history, two 
months before PET/CT examination found a tumour in left axillary. 
At first, she underwent lymphatic node ultrasonography, which re-
vealed large left axilla tumour and the next step tumour fine-needle 
aspiration (FNA) showed carcinomatose neoplasmatica. 
She was referred to breast ultrasonography and mammogra-
phy, which showed bilateral tumours (right breast 13 ¥ 12 mm, 
left breast 18 ¥ 13 mm) with BIRADS 5 so the patient underwent 
a core-needle biopsy. The results showed carcinoma invasivum NST 
G1 (Ki67 1%), ER (3+) 100% and HER-2 negative in both breasts. 
Repeated biopsy of the left axillary lymph node did not answer the 
question what the origin of this tumour was. 
Due to inconclusive examination, the patient was referred to 
PET/CT with 18F-FES (30’ after injection of 3.5 MBq/kg, Siemens Bio-
graph 64 PET). The study showed pathological uptakes of the 
radiopharmaceutical in both breast tumours (left with SUVmax 5.3 
Figure 1. A, B; right with SUVmax 1.9; Figure 1. C, D). There were 
no other pathological uptakes, especially in the left axilla tumour 
(Figure 1. B, C, D). The examination also showed enlarged cervical 
nodes without the radiotracer uptake.
To summarise, the examination revealed that lymph node pack-
age in left axilla and enlarged cervical nodes were not estrogen 
positive metastasis from breast cancer. 
Therefore, a core-needle biopsy of the left axilla lymph node 
was done with result of DLBCL Ki67 90%. 
For DLBCL staging PET/CT with 18F-FDG was performed (60’ 
after injection of 3 MBq/kg). Due to the fast progress of the illness in 
the left axilla, the patient could not raise arms above the head so 
the examination was done with arms along the body. 
The study showed very weak uptake of radiopharmaceuticals in 
both breast tumours with SUVmax 2.1 (Figure 2. E, F). The patho-
logical uptakes were present in the left axilla tumour and enlarged 
cervical nodes, with SUVmax up to 23.4 (Figure 2. F, G, H). There 
were no other pathological uptakes. 
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Discussion
Simultaneous breast cancer and DLBCL are an exceptional and 
rare situation. Literature describes only 2.9% of such cases. Therapy 
depends on the stage of advancement of concomitant diseases. In 
our case and other ones described in literature there was a problem 
with non-conclusive FNA of lymph nodes. Lack of clear results can 
arise from the low sensitivity of this method. PET/CT with 18F-FDG 
and 18F-FES performed along with FNA or core-needle biopsy al-
lows to establish the right diagnosis and the stage of both diseases. 
